Capital Investment Advisory Services’s VanEck Pharmaceutical ETF PPH Stock Holding History

Capital Investment Advisory Services’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-475	Closed	-$38.6K	–	1003
2023 Q4	$38.6K	Hold	475	–	–	﹤0.01%	701
2023 Q3	$37.9K	Hold	475	–	–	﹤0.01%	665
2023 Q2	$37.4K	Sell	475 -150	-24%	-$11.7K	﹤0.01%	635
2023 Q1	$48.5K	Sell	625 -220	-26%	-$17K	0.01%	600
2022 Q4	$65.7K	Sell	845 -20	-2%	-$1.48K	0.01%	592
2022 Q3	$58K	Sell	865 -10	-1%	-$737	0.01%	562
2022 Q2	$67K	Buy	+875	New	+$68.3K	0.01%	569

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

PCIA

Prime Capital Investment Advisors Overland Park, Kansas $10.3B AUM 25.54% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Capital Investment Advisory Services's PPH Position: Q1 2024 in Review

Capital Investment Advisory Services sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2024, closing a stake of 475 shares — an estimated $38.6K sold.

Capital Investment Advisory Services first reported a position in PPH in Q2 2022 and held it in 7 quarters. The position peaked at $67K in Q2 2022. 138 funds tracked by Wall St. Rank hold PPH as of Q1 2024.

Capital Investment Advisory Services reported no remaining VanEck Pharmaceutical ETF position as of Q1 2024 after selling out during the quarter.
Capital Investment Advisory Services sold 475 VanEck Pharmaceutical ETF shares in Q1 2024, an estimated $38.6K.
Capital Investment Advisory Services first reported a position in VanEck Pharmaceutical ETF in Q2 2022 and held it in 7 quarters.
Capital Investment Advisory Services's VanEck Pharmaceutical ETF position peaked at $67K in Q2 2022.
138 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2024.

Based on Capital Investment Advisory Services's 13F filing for Q1 2024, filed 25 Apr 2024.